In the latest quarter, 7 analysts provided ratings for CVRx CVRX, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.0, a high estimate of $22.00, and a low estimate of $14.00. This current average reflects an increase of 18.89% from the previous average price target of $15.14.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of CVRx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Alexander Nowak | Craig-Hallum | Raises | Buy | $22.00 | $20.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $22.00 | $17.00 |
| Alexander Nowak | Craig-Hallum | Raises | Buy | $20.00 | $15.00 |
| Frank Takkinen | Lake Street | Raises | Buy | $15.00 | $12.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $17.00 | $15.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $16.00 | $13.00 |
| Ross Osborn | Cantor Fitzgerald | Maintains | Overweight | $14.00 | $14.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CVRx. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVRx compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CVRx's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into CVRx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on CVRx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into CVRx's Background
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Breaking Down CVRx's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: CVRx displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 27.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVRx's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -97.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CVRx's ROE stands out, surpassing industry averages. With an impressive ROE of -21.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): CVRx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.71%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: CVRx's debt-to-equity ratio is below the industry average at 0.77, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
